In recent years, biologics targeting type 2 inflammation, including IL-4, IL-5, IL-13, and IgE, have demonstrated efficacy in treating severe cases of CRSwNP that are resistant to glucocorticoids and surgical interventions. Here, IL5 is linked to chronic rhinosinusitis with nasal polyps.